Background:Recent study revealed that the prognostic impact of the MPV (Mean platelet volume) /platelet count ratio in terms of survival in advanced non-small cell lung cancer. However, there has been no direct analysis of the survival impact of MPV in patients with mCRC.
Aim: The aim of the study is to evaluate the pretreatment MPV of patients with metastatic and non-metastatic colorectal cancer (non-mCRC) and also the prognostic significance of pretreatment MPV to progression in mCRC patients who have been treated with bevacizumab-combined chemotherapy.
Methods:Fifty-three metastatic and nighty-five non-metastatic colorectal cancer patients included into the study. Data on sex, age, lymph node status, MPV, platelet and platecrit (PCT) levels were obtained retrospectively from the patient’s medical records.
Results:The MPV was found to be significantly higher in the patients with mCRC compared patients with non-mCRC (7.895±1.060 versus 7.322±1.136, p=0.013). The benefit of bevacizumab on PFS was significantly greater among the patients with low MPV than patients with high MPV. The hazard ratio (HR) of disease progression was 0.41 (95% CI, 0.174-0.986; p=0.04).
Conclusions: In conclusion, despite the retrospective design and small sample size, MPV can be considered a prognostic factor for mCRC patients treated with bevacizumab-combined chemotherapy.